{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:19:58Z","timestamp":1787242798149,"version":"build-2736575974"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"\n Objective.<\/jats:title>\n Secukinumab, a fully human antiinterleukin 17A monoclonal antibody, is efficacious for the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). This study examined the immunogenicity of secukinumab in patients with PsA and AS exposed to secukinumab for up to 52 weeks.<\/jats:p>\n <\/jats:sec>\n \n Methods.<\/jats:title>\n Antibody bridging assays were used to assess the immunogenicity of secukinumab in patients with PsA [FUTURE 1\u20133 studies, and AS (MEASURE 1\u20134 studies)]. Evaluations were at baseline and at weeks 16 (AS only), 24, and 52. Treatment-emergent antidrug antibodies (TE-ADA) were defined as a positive ADA signal in \u2265 1 posttreatment sample in patients negative at baseline. Positive samples were analyzed for drug-neutralizing potential, and effect of TE-ADA on secukinumab pharmacokinetics, immunogenicity-related adverse events (AE), and efficacy through Week 52 were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results.<\/jats:title>\n Of 1414 treated PsA and 1164 treated AS patients with samples available for immunogenicity evaluation, 5 (0.35%) and 8 (0.69%), respectively, developed TE-ADA. All but 1 PsA patient were biologic-naive; two of the 5 PsA and one of the 8 AS patients received concomitant methotrexate, and two of the 8 AS patients received concomitant sulfasalazine. Associations between TE-ADA and secukinumab dose, frequency, or administration mode were not observed. Other than one PsA patient, all TE-ADA were non-neutralizing. No TE-ADA were associated with any AE. All TE-ADA were associated with normal secukinumab pharmacokinetics and none were associated with loss of secukinumab efficacy.<\/jats:p>\n <\/jats:sec>\n \n Conclusion.<\/jats:title>\n \n Secukinumab treatment was associated with a low (< 1%) incidence of immunogenicity in patients with PsA or AS. (\n clinicaltrials.gov<\/jats:ext-link>\n :\n NCT01392326<\/jats:ext-link>\n ;\n NCT01752634<\/jats:ext-link>\n ;\n NCT01989468<\/jats:ext-link>\n ;\n NCT01358175<\/jats:ext-link>\n ;\n NCT01649375<\/jats:ext-link>\n ;\n NCT02008916<\/jats:ext-link>\n ;\n NCT02159053<\/jats:ext-link>\n )\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3899\/jrheum.190116","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T12:24:12Z","timestamp":1560601452000},"page":"539-547","source":"Crossref","is-referenced-by-count":27,"title":["Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis"],"prefix":"10.3899","volume":"47","author":[{"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spindeldreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruvie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luminita","family":"Pricop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Jorge","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Shete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"2021110311500908000_47.4.539.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53"},{"key":"2021110311500908000_47.4.539.2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3781"},{"key":"2021110311500908000_47.4.539.3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8307-1"},{"key":"2021110311500908000_47.4.539.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2021110311500908000_47.4.539.5","first-page":"484","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Rheumatol"},{"key":"2021110311500908000_47.4.539.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"2021110311500908000_47.4.539.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"2021110311500908000_47.4.539.8","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"2021110311500908000_47.4.539.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2021110311500908000_47.4.539.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"2021110311500908000_47.4.539.11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2021110311500908000_47.4.539.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"2021110311500908000_47.4.539.13","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021110311500908000_47.4.539.14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2021110311500908000_47.4.539.15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: A randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021110311500908000_47.4.539.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2009.03.012"},{"key":"2021110311500908000_47.4.539.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"2021110311500908000_47.4.539.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.406"},{"key":"2021110311500908000_47.4.539.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220"},{"key":"2021110311500908000_47.4.539.20","first-page":"752","article-title":"Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis","volume":"176","author":"Reich","year":"2017","journal-title":"Br J Rheumatol"},{"key":"2021110311500908000_47.4.539.21","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.250"},{"key":"2021110311500908000_47.4.539.22","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration . Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins; Guidance. [Internet. Accessed September 16, 2019.] Available from: www.regulations.gov\/document?D=FDA-2009-D-0539-0002"},{"key":"2021110311500908000_47.4.539.23","unstructured":"European Medicines Agency . Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. [Internet. Accessed September 16, 2019.] Available from: www.ema.europa.eu\/documents\/scientific-guideline\/draft-guideline-immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-revision-1_en.pdf"},{"key":"2021110311500908000_47.4.539.24","unstructured":"European Medicines Agency . Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. [Internet. Accessed September 16, 2019.] Available from: www.ema.europa.eu\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf"},{"key":"2021110311500908000_47.4.539.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.01.001"},{"key":"2021110311500908000_47.4.539.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.06.002"},{"key":"2021110311500908000_47.4.539.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2009.03.012"},{"key":"2021110311500908000_47.4.539.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.020"},{"key":"2021110311500908000_47.4.539.29","doi-asserted-by":"publisher","DOI":"10.1159\/000076746"},{"key":"2021110311500908000_47.4.539.30","unstructured":"US Food and Drug Administration . Assay development and validation for immunogenicity testing of therapeutic protein products. [Internet. Accessed September 16, 2019.] Available from: www.fda.gov\/downloads\/drugs\/guidances\/UCM192750.pdf"},{"key":"2021110311500908000_47.4.539.31","doi-asserted-by":"crossref","first-page":"5069678","DOI":"10.1155\/2016\/5069678","article-title":"Evaluation of multiple immunoassay technology platforms to select the anti-drug antibody assay exhibiting the most appropriate drug and target tolerance","volume":"2016","author":"Collet-Brose","year":"2016","journal-title":"J Immunol Res"},{"key":"2021110311500908000_47.4.539.32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"2021110311500908000_47.4.539.33","first-page":"697","article-title":"Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy","volume":"29","author":"Snir","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2021110311500908000_47.4.539.34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/OARRR.S17118","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis","volume":"3","author":"Mihara","year":"2011","journal-title":"Open Access Rheumatol"},{"key":"2021110311500908000_47.4.539.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009234107"},{"key":"2021110311500908000_47.4.539.36","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.2.7909"},{"key":"2021110311500908000_47.4.539.37","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"2021110311500908000_47.4.539.38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/19420862.2015.1136761","article-title":"Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity","volume":"8","author":"Karle","year":"2016","journal-title":"MAbs"},{"key":"2021110311500908000_47.4.539.39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13555-018-0220-y","article-title":"Secukinumab demonstrates significantly lower immunogenicity potential compared to ixekizumab","volume":"8","author":"Spindeldreher","year":"2018","journal-title":"Dermatol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.190116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T14:52:50Z","timestamp":1635951170000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.190116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.3899\/jrheum.190116"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.190116","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]}}}